Pancreatic Cancer Research

ResearcherFujian Medical UniversityNo recent work listed

Long Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4925-5162; OpenAlex author ID A5101555634. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers

Papers 9

  1. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Co-author DOI 10.1016/j.celrep.2022.110813↗
  2. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-022-02343-z↗
  3. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  4. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s13045-021-01072-8↗
  5. Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-κB subunit RelA trans-regulation that can be suppressed by eugenic acid. Co-author DOI 10.1016/j.biopha.2020.110830↗
  6. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. First author DOI 10.1186/s13148-020-00961-y↗
  7. SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer . Co-author DOI 10.21203/rs.3.rs-95104/v1↗
  8. RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment. Co-author DOI 10.1186/s13046-018-0986-x↗
  9. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. Co-author DOI 10.1016/j.canlet.2016.09.027↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yifeng Tian · 9 shared papers, 2016–2022 · strength 0.97
  2. Shi Chen · 9 shared papers, 2016–2022 · strength 0.97
  3. Can Yang · 6 shared papers, 2020–2022 · strength 0.68
  4. Cheng‐Yu Liao · 5 shared papers, 2020–2022 · strength 0.61
  5. Zuwei Wang · 5 shared papers, 2020–2022 · strength 0.61
  6. Baiyong Shen · 5 shared papers, 2019–2022 · strength 0.55
  7. Ge Li · 3 shared papers, 2020–2021 · strength 0.33
  8. Qian Zhan · 3 shared papers, 2020–2021 · strength 0.32
  9. Jiangzhi Chen · 3 shared papers, 2019–2020 · strength 0.30
  10. Yaodong Wang · 2 shared papers, 2021–2022 · strength 0.25
  11. Yao-Dong Wang · 2 shared papers, 2020 · strength 0.21
  12. Yaodong Wang · 2 shared papers, 2016–2020 · strength 0.16
  13. Zhi‐Wen Chen · 1 shared paper, 2022 · strength 0.15
  14. Huatian Luo · 1 shared paper, 2020 · strength 0.11
  15. Zhixiang Jian · 1 shared paper, 2020 · strength 0.11
  16. Huixing Chen · 1 shared paper, 2019 · strength 0.09
  17. Chenghong Peng · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.